Antithrombin heparin binding site deficiency: A challenging diagnosis of a not so benign thrombophilia

Thrombosis Research

Volumn 135, Issue 6, 2015, Pages 1179-1185

  Orlando, Christelle ^a   Heylen, Olivier ^a   Lissens, Willy ^a   Jochmans, Kristin ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Antithrombin deficiency; Arterial Thrombosis; Mutation; Thrombophilia; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ANTITHROMBIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 5; HEPARIN; SERPINC1 PROTEIN, HUMAN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ANTITHROMBIN HEPARIN BINDING SITE DEFICIENCY; ARTERY THROMBOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEART INFARCTION; HUMAN; INCUBATION TIME; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; ADOLESCENT; ANTITHROMBIN III DEFICIENCY; ARTERY; BINDING SITE; BLOOD; CHEMISTRY; CHILD; GENETICS; HETEROZYGOTE; HOMOZYGOTE; INFANT; MIDDLE AGED; MUTATION; NEWBORN; PATHOPHYSIOLOGY; PHENOTYPE; PRESCHOOL CHILD; REPRODUCIBILITY; RISK; SENSITIVITY AND SPECIFICITY; THROMBOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; ANTITHROMBINS; ARTERIES; BINDING SITES; CHILD; CHILD, PRESCHOOL; FACTOR V; FEMALE; HEPARIN; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THROMBOPHILIA; THROMBOSIS; YOUNG ADULT;

EID: 84929510353     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.03.013     Document Type: Article

References (37)

1. K. Kottke-Marchant, and A. Duncan Antithrombin deficiency: issues in laboratory diagnosis Arch Pathol Lab Med 11 2002 1326 1336
2. M.M. Patnaik, and S. Moll Inherited antithrombin deficiency: a review Haemophilia 6 2008 1229 1239
3. H.H. van Boven, P.H. Reitsma, F.R. Rosendaal, T.A. Bayston, V. Chowdhury, and K.A. Bauer Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency Thromb Haemost 3 1996 417 421
4. S. Kuhle, D.A. Lane, K. Jochmanns, C. Male, P. Quehenberger, and K. Lechner Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism Thromb Haemost 4 2001 1007 1011
5. J. Conard, L. Bara, M.H. Horellou, and M.M. Samama Bovine or human thrombin in amidolytic at III assays. Influence of heparin cofactor II Thromb Res 6 1986 873 878
6. J. Corral, D. Hernandez-Espinosa, J.M. Soria, R. Gonzalez-Conejero, A. Ordonez, and J.R. Gonzalez-Porras Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis Blood 10 2007 4258 4263
7. P.C. Cooper, F. Coath, M.E. Daly, and M. Makris The phenotypic and genetic assessment of antithrombin deficiency Int J Lab Hematol 3 2011 227 237
8. P.L. Harper, M. Daly, J. Price, P.F. Edgar, and R.W. Carrell Screening for heparin binding variants of antithrombin J Clin Pathol 6 1991 477 479
9. K. Jochmans, W. Lissens, R. Vervoort, S. Peeters, W.M. De, and I. Liebaers Antithrombin-Gly 424 Arg: a novel point mutation responsible for type 1 antithrombin deficiency and neonatal thrombosis Blood 1 1994 146 151
10. S. Miyakis, M.D. Lockshin, T. Atsumi, D.W. Branch, R.L. Brey, and R. Cervera International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost 2 2006 295 306
11. K. Javela, S. Engelbarth, L. Hiltunen, P. Mustonen, and M. Puurunen Great discrepancy in antithrombin activity measured using five commercially available functional assays Thromb Res 1 2013 132 137
12. S.R. Kristensen, B. Rasmussen, S. Pedersen, and L. Bathum Detecting antithrombin deficiency may be a difficult task-more than one test is necessary J Thromb Haemost 3 2007 617 618
13. M. Puurunen, P. Salo, S. Engelbarth, K. Javela, and M. Perola Type II Antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population - clinical picture J Thromb Haemost 11 2013 1844 1849
14. M. Merz, M. Bohm-Weigert, S. Braun, P.C. Cooper, R. Fischer, and K. Hickey Clinical multicenter evaluation of a new FXa-based Antithrombin assay Int J Lab Hematol 5 2011 498 506
15. B. Kovacs, Z. Bereczky, Z. Olah, R. Gindele, A. Kerenyi, and A. Selmeczi The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency Am J Clin Pathol 5 2013 675 679
16. C. Demers, P. Henderson, M.A. Blajchman, M.J. Wells, L. Mitchell, and M. Johnston An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition Thromb Haemost 3 1993 231 235
17. R.A. Marlar, and J.N. Gausman Laboratory testing issues for protein C, protein S, and antithrombin Int J Lab Hematol 3 2014 289 295
18. S.T. Olson, K.R. Srinivasan, I. Bjork, and J.D. Shore Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction J Biol Chem 21 1981 11073 11079
19. M.C. Owen, J.Y. Borg, C. Soria, J. Soria, J. Caen, and R.W. Carrell Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His Blood 5 1987 1275 1279
20. J.S. Ungerstedt, S. Schulman, N. Egberg, J. Antovic, and N. Blomback Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 6 2002 2271 2272
21. M.A. Blajchman, F. Fernandez-Rachubinski, W.P. Sheffield, R.C. Austin, and S. Schulman Antithrombin-III-Stockholm: a codon 392 (Gly - Asp) mutation with normal heparin binding and impaired serine protease reactivity Blood 6 1992 1428 1434
22. G. Finazzi, R. Caccia, and T. Barbui Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases Thromb Haemost 4 1987 1094
23. A. Girolami, A.R. Lazzaro, and P. Simioni The relationship between defective heparin cofactor activities and thrombotic phenomena in AT III abnormalities Thromb Haemost 1 1988 121
24. R.J. Olds, D.A. Lane, V. Chowdhury, G. Sas, I. Pabinger, and K. Auberger (ATT) trinucleotide repeats in the antithrombin gene and their use in determining the origin of repeated mutations Hum Mutat 1 1994 31 41
25. R.J. Olds, D.A. Lane, M. Boisclair, G. Sas, S.C. Bock, and S.L. Thein Antithrombin Budapest 3. An antithrombin variant with reduced heparin affinity resulting from the substitution L99F FEBS Lett 3 1992 241 246
26. N. Sarper, C. Orlando, U. Demirsoy, S.A. Gelen, and K. Jochmans Homozygous Antithrombin Deficiency in Adolescents Presenting With Lower Extremity Thrombosis and Renal Complications: Two Case Reports From Turkey J Pediatr Hematol Oncol 36 2014 e190 e192
27. I. Martinez-Martinez, J. Navarro-Fernandez, A. Ostergaard, R. Gutierrez-Gallego, J. Padilla, and N. Bohdan Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism Blood 4 2012 900 904
28. V. Chowdhury, D.A. Lane, B. Mille, K. Auberger, S. Gandenberger-Bachem, and I. Pabinger Homozygous antithrombin deficiency: report of two new cases (99 Leu to Phe) associated with arterial and venous thrombosis Thromb Haemost 2 1994 198 202
29. K. Roman, E. Rosenthal, and R. Razavi Pulmonary arterial thrombosis in a neonate with homozygous deficiency of antithrombin III: successful outcome following pulmonary thrombectomy and infusions of antithrombin III concentrate Cardiol Young 3 2000 275 278
30. C.Y. Vossen, and F.R. Rosendaal Risk of arterial thrombosis in carriers of familial thrombophilia J Thromb Haemost 4 2006 916 918
31. B.K. Mahmoodi, J.L. Brouwer, N.J. Veeger, and J. Van Der Meer Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study Circulation 16 2008 1659 1667
32. B. Luxembourg, A. Pavlova, C. Geisen, M. Spannagl, F. Bergmann, and M. Krause Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency Thromb Haemost 2 2014 249 257
33. V. Roldan, A. Ordonez, F. Marin, E. Zorio, J.M. Soria, and A. Minano Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis Thromb Haemost 3 2009 483 486
34. A. Mushunje, A. Zhou, R.W. Carrell, and J.A. Huntington Heparin-induced substrate behavior of antithrombin Cambridge II Blood 12 2003 4028 4034
35. J. Wang, Y. Wang, J. Wang, J. Gao, C. Tong, and C. Manithody Antithrombin is protective against myocardial ischemia and reperfusion injury J Thromb Haemost 6 2013 1020 1028
36. C.Y. Vossen, J. Conard, J. Fontcuberta, M. Makris, F.J. van der Meer, and I. Pabinger Familial thrombophilia and lifetime risk of venous thrombosis J Thromb Haemost 9 2004 1526 1532
37. C.Y. Vossen, J. Conard, J. Fontcuberta, M. Makris, F.J. van der Meer, and I. Pabinger Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) J Thromb Haemost 3 2005 459 464